Hepatocellular carcinoma: Epidemiology, surveillance, and diagnosis

Seminars in Liver Disease

Volumn 30, Issue 1, 2010, Pages 3-16

  Sherman, Morris ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

fetoprotein; AFP L3; Desgamma carboxyprothrombin; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; Surveillance; Ultrasonography

Indexed keywords

ALGORITHM; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; SEROLOGY;

CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; EARLY DETECTION OF CANCER; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; OBSERVATION; PRECANCEROUS CONDITIONS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 77349084899     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0030-1247128     Document Type: Review

References (94)

1. Bosch F X., Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004 127 (5, Suppl 1) S5-S16
2. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987 47 (18) 4967-4972
3. Taylor-Robinson S D., Foster G R., Arora S, Hargreaves S, Thomas H C. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997 350 (9085) 1142-1143
4. Deuffic S, Poynard T, Buffat L, Valleron A J. Trends in primary liver cancer. Lancet 1998 351 (9097) 214-215
5. Stroffolini T, Andreone P, Andriulli A et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998 29 (6) 944-952
6. El-Serag H B., Mason A C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999 340 (10) 745-750
7. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009 44 (Suppl 19) 102-107
8. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008 48 (1) 137-145 (Pubitemid 351980469)
9. King H, Locke F B. Cancer mortality among Chinese in the United States. J Natl Cancer Inst 1980 65 (5) 1141-1148 (Pubitemid 11215044)
10. Rosenblatt K A., Weiss N S., Schwartz S M. Liver cancer in Asian migrants to the United States and their descendants. Cancer Causes Control 1996 7 (3) 345-350
11. McCredie M, Williams S, Coates M. Cancer mortality in East and Southeast Asian migrants to New South Wales, Australia, 1975-1995. Br J Cancer 1999 79 (7-8) 1277-1282 (Pubitemid 29087911)
12. Beasley R P., Hwang L Y., Lin C C., Chien C S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981 2 (8256) 1129-1133
13. Sakuma K, Saitoh N, Kasai M et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology 1988 8 (6) 1642-1646
14. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997 112 (2) 463-472
15. Bruix J, Barrera J M., Calvet X et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989 2 (8670) 1004-1006
16. Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998 28 (6) 1687-1695
17. Sun C A., Wu D M., Lin C C. et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003 157 (8) 674-682
18. Ikeda K, Saitoh S, Koida I et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993 18 (1) 47-53
19. Benvegn L, Fattovich G, Noventa F et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994 74 (9) 2442-2448
20. Cottone M, Turri M, Caltagirone M et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994 21 (6) 1029-1034
21. Borzio M, Bruno S, Roncalli M et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 1995 108 (3) 812-817
22. Pateron D, Ganne N, Trinchet J C. et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994 20 (1) 65-71
23. Colombo M, de Franchis R, Del Ninno E et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991 325 (10) 675-680
24. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 19802004. Hepatology 2008 48 (1) 137-145 (Pubitemid 351980469)
25. Fargion S, Fracanzani A L., Piperno A et al. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 1994 20 (6) 1426-1431
26. Caballería L, Parés A, Castells A, Ginés A, Bru C, Rodés J. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 2001 96 (4) 1160-1163
27. Goedert J J., Second Multicenter Hemophilia Cohort Study. Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 20012003. Haemophilia 2005 11 (5) 516-528
28. Livraghi T, Meloni F, Di Stasi M et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008 47 (1) 82-89
29. Sala M, Llovet J M., Vilana R et al, Barcelona Clínic Liver Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004 40 (6) 1352-1360
30. Lu S N., Wang J H., Chen P F. et al. Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults. Cancer Epidemiol Biomarkers Prev 2008 17 (7) 1813-1821
31. Mima S, Sekiya C, Kanagawa H et al. Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan. J Gastroenterol Hepatol 1994 9 (4) 361-365
32. Yu E W., Chie W C., Chen T H. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients? Cancer J 2004 10 (5) 317-325
33. Chan A C., Poon R T., Ng K K., Lo C M., Fan S T., Wong J. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann Surg 2008 247 (4) 666-673
34. Stravitz R T., Heuman D M., Chand N et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008 121 (2) 119-126
35. Chen J G., Parkin D M., Chen Q G. et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003 10 (4) 204-209
36. Zhang B H., Yang B H., Tang Z Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004 130 (7) 417-422
37. Sarasin F P., Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996 101 (4) 422-434
38. Arguedas M R., Chen V K., Eloubeidi M A., Fallon M B. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003 98 (3) 679-690
39. Patel D, Terrault N A., Yao F Y., Bass N M., Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005 3 (1) 75-84
40. Lin O S., Keeffe E B., Sanders G D., Owens D K. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004 19 (11) 1159-1172
41. Thompson Coon J, Rogers G, Hewson P et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 2008 98 (7) 1166-1175
42. Ishizawa T, Hasegawa K, Aoki T et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008 134 (7) 1908-1916
43. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005 42 (5) 1208-1236
44. Chen C J., Yang H I., Su J et al, REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 295 (1) 65-73
45. Tong M J., Hsien C, Song J J. et al. Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. Dig Dis Sci 2009 54 (6) 1337-1346
46. Chen T H., Chen C J., Yen M F. et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 2002 98 (2) 257-261
47. Chen G, Lin W, Shen F, Iloeje U H., London W T., Evans A A. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006 101 (8) 1797-1803
48. Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008 57 (1) 84-90
49. Snchez-Tapias J M., Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in Western patients. Gastroenterology 2002 123 (6) 1848-1856
50. Yang H I., Yeh S H., Chen P J. et al, REVEAL-HBV Study Group. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008 100 (16) 1134-1143
51. Yuen M F., Tanaka Y, Fong D Y. et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009 50 (1) 80-88
52. Chen C J., Yang H I., Iloeje U H. et al. A risk function nomogram for predicting HCC in patients with chronic hepatitis B: The REVEAL.-HBV Study. J Hepatol 2007 46 (Suppl 1) S180
53. Lok A S., Seeff L B., Morgan T R. et al, HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009 136 (1) 138-148
54. Trevisani F, D'Intino P E., Morselli-Labate A M. et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001 34 (4) 570-575
55. Pateron D, Ganne N, Trinchet J C. et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. [see comments] J Hepatol 1994 20 (1) 65-71
56. Marrero J A., Su G L., Wei W et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003 37 (5) 1114-1121
57. Durazo F A., Blatt L M., Corey W G. et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2008 23 (10) 1541-1548
58. Sterling R K., Jeffers L, Gordon F et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009 7 (1) 104-113
59. Di Bisceglie A M., Hoofnagle J H. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989 64 (10) 2117-2120
60. Di Bisceglie A M., Sterling R K., Chung R T. et al, HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005 43 (3) 434-441
61. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001 34 (4) 603-605
62. Zhou X D., Tang Z Y., Fan J et al. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2009 135 (8) 1073-1080
63. Welzel T M., Graubard B I., El-Serag H B. et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007 5 (10) 1221-1228
64. Fujiyama S, Izuno K, Yamasaki K, Sato T, Taketa K. Determination of optimum cutoff levels of plasma des-gamma-carboxy prothrombin and serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristic curves. Tumour Biol 1992 13 (5-6) 316-323
65. Okuda H, Nakanishi T, Takatsu K et al. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 1999 85 (4) 812-818
66. Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol 2007 42 (12) 962-968
67. Carr B I., Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 2007 52 (3) 776-782
68. Leerapun A, Suravarapu S V., Bida J P. et al. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol 2007 5 (3) 394-402, quiz 267
69. Sterling R K., Jeffers L, Gordon F et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol 2007 102 (10) 2196-2205
70. Capurro M, Wanless I R., Sherman M et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003 125 (1) 89-97
71. Yamauchi N, Watanabe A, Hishinuma M et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005 18 (12) 1591-1598
72. Marrero J A., Romano P R., Nikolaeva O et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 2005 43 (6) 1007-1012
73. Bolondi L, Sofia S, Siringo S et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001 48 (2) 251-259
74. Chen T H., Chen C J., Yen M F. et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 2002 98 (2) 257-261
75. Larcos G, Sorokopud H, Berry G, Farrell G C. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. AJR Am J Roentgenol 1998 171 (2) 433-435
76. Zhang B, Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999 6 (2) 108-110
77. Kobayashi K, Sugimoto T, Makino H et al. Screening methods for early detection of hepatocellular carcinoma. Hepatology 1985 5 (6) 1100-1105
78. Takayasu K, Moriyama N, Muramatsu Y et al. The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients. AJR Am J Roentgenol 1990 155 (1) 49-54
79. Miller W J., Baron R L., Dodd G D. III, Federle M P. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients. Radiology 1994 193 (3) 645-650
80. Santagostino E, Colombo M, Rivi M et al, Study Group of the Association of Italian Hemophilia Centers. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003 102 (1) 78-82
81. Trevisani F, Cantarini M C., Labate A M. et al, Italian Liver Cancer (ITALICA) group. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol 2004 99 (8) 1470-1476
82. Kim D Y., Han K H., Ahn S H. et al. Semiannual surveillance for hepatocellular carcinoma improved patient survival compared to annual surveillance (Korean experience). Hepatology 2007 46 (Suppl 1) 403A
83. Nicolau C, Vilana R, Catal V et al. Importance of evaluating all vascular phases on contrast-enhanced sonography in the differentiation of benign from malignant focal liver lesions. AJR Am J Roentgenol 2006 186 (1) 158-167
84. Iannaccone R, Laghi A, Catalano C et al. Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology 2005 234 (2) 460-467
85. Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view. Liver Transpl 2004 10 (2, Suppl 1) S3-S8
86. Nakashima T, Kojiro M. Hepatocellular Carcinoma. Tokyo Springer-Verlag 1987
87. International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009 49 (2) 658-664
88. Libbrecht L, Severi T, Cassiman D et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006 30 (11) 1405-1411
89. Coston W M., Loera S, Lau S K. et al. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol 2008 32 (3) 433-444
90. Park Y N., Kojiro M, Di Tommaso L et al. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer 2007 109 (5) 915-923
91. Iwasaki M, Furuse J, Yoshino M, Ryu M, Moriyama N, Mukai K. Sonographic appearances of small hepatic nodules without tumor stain on contrast-enhanced computed tomography and angiography. J Clin Ultrasound 1998 26 (6) 303-307
92. Rimola J, Forner A, Reig M et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 2009 50 (3) 791-798
93. Forner A, Vilana R, Ayuso C et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008 47 (1) 97-104
94. Khalili K, Kim T Y., Jang H J., Haider M A., Guindi M, Sherman M. Implementation of AASLD hepatocellular carcinoma practice guidelines in north america:two years of experience. Hepatology 2008 48 (Suppl 1) 362A